肺炎支原体坏死性肺炎和细菌性坏死性肺炎临床特征分析
收稿日期: 2023-02-07
网络出版日期: 2024-03-06
Clinical characteristics analysis of Mycoplasma pneumoniae necrotizing pneumonia and bacterial necrotizing pneumonia
Received date: 2023-02-07
Online published: 2024-03-06
目的 分析肺炎支原体坏死性肺炎(MPNP)和细菌性坏死性肺炎(BNP)的临床特征,观察炎性指标变化特点。方法 回顾性分析2016年至2021年收治并诊断为MPNP和BNP的临床资料共72例。结果 MPNP组43例,BNP组29例,前者年龄中位数7.9岁,后者1.9岁(P<0.01)。BNP组出现气促、三凹征和无创呼吸机使用的比例分别为79.3%、37.9%和51.7%,MPNP组分别为37.2%、9.3%和18.6%(P<0.05)。BNP组病原以肺炎链球菌和金黄色葡萄球菌为主,占病例总数76%。BNP组病程3天内C反应蛋白中位数83 mg/L,降钙素原中位数29.9 ng/mL,均高于MPNP组14 mg/L和0.1 ng/mL(P<0.05)。MPNP组在病程4~7天和8~14天中性粒细胞比例中位数分别为78.2%和80.4%,BNP组为65.8%和59.8%(P<0.05)。两组白细胞总数在病程前3天差异无统计学意义(P>0.05)。MPNP组血D-二聚体中位数4.1 mg/L高于BNP组3 mg/L(P<0.05)。MPNP组胸水白细胞以单核细胞为主,BNP组以多核细胞为主,BNP组胸水糖(2±2)mmol/L明显低于MPNP组(6±2)mmol/L(P<0.01)。MPNP组肺部发生空洞坏死的时间为(23.4±10.0)天,BNP组为(10.4±5.7)天(P<0.01)。MPNP组8例可见肺动脉栓塞,支气管镜下7例可见塑型形成,21例遗留有管腔狭窄、闭塞后遗症。BNP组12例出现脓气胸。结论 BNP组在病程前3天C-反应蛋白和降钙素原明显升高;容易发生呼吸困难及脓气胸。MPNP组中性粒细胞比例在病程4天以后明显升高,血D-二聚体水平较高,肺部空洞坏死发生晚,容易发生肺动脉栓塞,支气管镜下可见塑型,管腔狭窄、闭塞后遗症发生率较高。
吉晓丹 , 赵顺英 . 肺炎支原体坏死性肺炎和细菌性坏死性肺炎临床特征分析[J]. 临床儿科杂志, 2024 , 42(3) : 193 -197 . DOI: 10.12372/jcp.2024.23e0044
Objective To analyze the clinical features of Mycoplasma pneumoniae necrotizing pneumonia (MPNP) and bacterial necrotizing pneumonia (BNP) and to observe the changes of inflammatory indicators. Methods The clinical data of 72 children diagnosed with MPNP or BNP from 2016 to 2021 were retrospectively analyzed. Results There were 43 children in MPNP group and 29 children in BNP group. The median age was 7.9 years in MPNP group and 1.9 years in BNP group (P<0.01). In the BNP group, the rates of shortness of breath, triple concave sign, and non-invasive ventilator use were 79.3%, 37.9%, and 51.7%, respectively, whereas in the MPNP group, the rates were 37.2%, 9.3%, and 18.6% (P<0.05). Streptococcus pneumoniae and Staphylococcus aureus were the predominant pathogens in the BNP group, making up 76% of all cases. The median C-reactive protein and procalcitonin levels in the BNP group within 3 days of disease course were 83 mg/L and 29.9 ng/mL respectively, which were higher than those in the MPNP group (14 mg/L and 0.1 ng/mL) (P<0.05). At days 4-7 and 8-14 of disease course, the median neutrophil ratio in MPNP group was 78.2% and 80.4%, while that in BNP group was 65.8% and 59.8% (P<0.05). There was no significant difference in the total number of white blood cells between the two groups at days 1-3 of disease course (P>0.05). The median blood D-dimer concentration in the MPNP group was 4.1 mg/L, which was higher than that in the BNP group (3 mg/L) (P<0.05). The pleural fluid leukocytes in MPNP group were mainly mononuclear cells, while those in the BNP group were mainly multinucleated cells. The glucose level of pleural fluid in BNP group was (2±2) mmol/L, which was significantly lower than that in the MPNP group [(6±2) mmol/L, P<0.01)]. The time of pulmonary cavity necrosis in MPNP group was (23.4±10.0) days, while that in BNP group was (10.4±5.7) days (P<0.01). In MPNP group, pulmonary embolism was observed in 8 cases, bronchoscopic plastic formation was observed in 7 cases, and sequelae (lumen stenosis and occlusion) were observed in 21 cases. Pyopneumothorax occurred in 12 cases of BNP group. Conclusions In BNP group, C-reactive protein and procalcitonin increased significantly at days 1-3 of disease course. The children in BNP group were prone to dyspnea and pyopneumothorax. In MPNP group, the proportion of neutrophil increased significantly after 4 days of disease course, the level of D-dimer in blood was higher, the occurrence of pulmonary cavity necrosis was late, and pulmonary embolism was easy to occur, and the plastic formation could be seen under bronchoscopy, and the incidence of sequelae of lumen stenosis and occlusion was high.
Key words: necrotizing pneumonia; Mycoplasma pneumoniae; bacteria; child
[1] | de Benedictis FM, Carloni I. Management of necrotizing pneumonia in children: Time for a patient-oriented approach[J]. Pediatr Pulmonol, 2019, 54(9): 1351-1353. |
[2] | 戴菱蔓. 儿童坏死性肺炎的研究进展[J]. 国际儿科学杂志, 2021, 48(3): 163-167. |
[3] | 周云连, 刘金荣, 易秋维, 等. 儿童坏死性肺炎病原学的多中心回顾性研究[J]. 中华儿科杂志, 2021, 59(8): 658-664. |
[4] | 中华人民共和国国家健康委员会, 国家中医药局. 儿童社区获得性肺炎诊疗规范(2019年版)[J]. 中华临床感染病杂志, 2019, 12(1): 6-13. |
[5] | 郑英兰. 儿童细菌性与支原体肺炎坏死性肺炎的临床及CT影像学表现分析[D]. 重庆: 重庆医科大学, 2022. |
[6] | Zheng B, Zhao J, Cao L. The clinical characteristics and risk factors for necrotizing pneumonia caused by Mycoplasma pneumoniae in children[J]. BMC Infect Dis, 2020, 20(1): 391. |
[7] | Sawicki GS, Lu FL, Valim C, et al. Necrotising pneumonia is an increasingly detected complication of pneumonia in children[J]. Eur Respir J, 2008, 31(6): 1285-1291. |
[8] | 张园园, 戴菱蔓, 周云连, 等. 儿童细菌性坏死性肺炎与肺炎支原体坏死性肺炎临床特征及预后比较[J]. 中华儿科杂志, 2019, 57(8): 625-630. |
[9] | 卓裕霏, 刘金荣, 李惠民, 等. 肺炎支原体坏死性肺炎特征和预测因素分析[J]. 中国实用儿科杂志, 2020, 35(12): 973-976. |
[10] | Neeser OL, Vukajlovic T, Felder L, et al. A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection[J]. Clin Chem Lab Med, 2019, 57(10): 1638-1646. |
[11] | Ness-Cochinwala M, Kobaitri K, Totapally BR. Characteristics and outcomes of children with necrotizing pneumonia[J]. Pediatr Crit Care Med, 2021, 22(12): e640-e643. |
[12] | 黄倩, 曾赛珍, 陈玲玲, 等. 36例儿童坏死性肺炎临床特征分析[J]. 中国小儿急救医学, 2023, 30(2): 115-121. |
[13] | 谭静, 李竹霞, 雷银兰, 等. 儿童肺脓肿94例临床分析[J]. 临床儿科杂志, 2020, 38(10): 730-735. |
[14] | 胡亚美, 江载芳, 申昆玲, 等. 诸福棠实用儿科学[M]. 8 版. 北京人民卫生出版社, 1828-1829. |
[15] | 王敏敏, 严永东. 儿童坏死性肺炎诊治进展[J]. 国际儿科学杂志, 2021, 48(8): 529-533 |
[16] | Cha SI, Shin KM, Jeon KN, et al. Clinical relevance and characteristics of pleural effusion in patients with Mycoplasma pneumoniae pneumonia[J]. Scand J Infect Dis, 2012, 44(10): 793-797. |
[17] | Tanaka H. Correlation between radiological and pathological findings in patients with Mycoplasma pneumoniae pneumonia[J]. Front Microbiol, 2016, 7: 695. |
[18] | 刘金荣, 徐保平, 李惠民, 等. 肺炎链球菌坏死性肺炎20例诊治分析[J]. 中华儿科杂志, 2012, 50(6): 431-434. |
[19] | 刘娜, 马静, 孟晨, 等. 肺炎支原体感染引起儿童心脏栓塞10例临床分析[J]. 中华实用儿科临床杂志, 2021, 36(16): 1253-1256. |
[20] | Yang B, Zhang W, Gu W, et al. Differences of clinical features and prognosis between Mycoplasma pneumoniae necrotizing pneumonia and non-Mycoplasma pneumoniae necrotizing pneumonia in children[J]. BMC Infect Dis, 2021, 21(1): 797. |
[21] | Sun LL, Ye C, Zhou YL, et al. Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe Mycoplasma Pneumoniae pneumonia[J]. Pediatr Infect Dis J, 2020, 39(3): 177-183. |
/
〈 |
|
〉 |